2021 Presenting Companies Transactions

KiOmed Pharma

Presented at ACCESS CHINA event 2021

(26 September, 2022, Shanghai, China ) HERSTAL, Belgium & SHANGHAI–KiOmed Pharma, a Belgian biotechnology company with a focus on the development, manufacture and distribution of safe and effective medical devices based on a medical-grade highly pure natural chitosan-derivative, and Hansoh Pharmaceutical Group Company Limited (SEHK: 3692), a leading biopharmaceutical company in Asia, today announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis, in China’s mainland, Macau and Taiwan (the territory). YAFO Capital (Shanghai) acted as advisor on this transaction for KiOmed Pharma.

Karus Therapeutics Ltd.

Presented at ACCESS CHINA event 2021

(14 July, 2022, Shanghai, China ) China’s biotech company Convalife (Shanghai) Co., Ltd. (“Convalife Pharmaceuticals ”) announced the closing of the global acquisition between Convalife Pharmaceuticals and British company Karus Therapeutics Ltd. (“Karus”) to acquire Karus’ CVL237(KA2237) (phosphatidylinositol-3-kinase PI3K β/δ dual selective inhibitor) worldwide rights. Prior to this, Convalife obtained the Greater China right of CVL237. YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Karus Therapeutics.

Propella Therapeutics, Inc.

Presented at ACCESS CHINA event 2021

PITTSBORO, N.C., and NANJING, JIANGSU April 7th, 2022 –Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm), a research-based pharmaceutical enterprise and leading manufacturer in PPI and oncology medications, today announced that the companies have entered into an exclusive licensing agreement for its osteoarthritis product, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis (OA) of the knee.

Sinotau Pharmaceutical

Presented at ACCESS CHINA event 2021

SHANGHAI, SUZHOU, BEIJING China, Recently (Sinotau announcement) — Sinotau Pharmaceutical (“Sinotau”), a pharmaceutical company focused on deploying a variety of targeted therapy and accurate diagnosis radiopharmaceutical, entered into a license agreement with Duality Biologics (“Duality”) which grants Duality the right of selected monoclonal antibody for specific tumor target. Duality will further develop it into a Best-in-class ADC drug based on the Duality Immune Toxin Antibody Conjugate (DITAC) technology platform.

Biosplice Therapeutics, Inc.

Presented at ACCESS CHINA event 2021

September, 2021 – Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, and Haisco Pharmaceutical Group Co., Ltd. (“Haisco”), a pharmaceutical company based in the People’s Republic of China (“China”), announced the execution of a licensing agreement which grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal conditions in China.
YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Biosplice Therapeutics.